SOURCE-LINKED STUDY SUMMARY
Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults.
Full paper summarizedQuality not appraised
- What was studied
- A randomized proof-of-concept trial tested whether daily urolithin A could improve muscle strength, exercise performance, and mitochondrial-health biomarkers in middle-aged adults; peak power output was the prespecified primary endpoint.
- Who / model studied
- Untrained, overweight middle-aged adults with low aerobic endurance were randomized at a single center.
- Studied dose & schedule
- Participants received oral urolithin A at one of two tested daily doses or placebo for four months.
- What the study found
- Hamstring average peak torque improved by 12% and 9.8% versus placebo in the two urolithin A groups. Lean and fat mass did not change, and adverse-event rates did not significantly differ between groups.
- Limitations & context
- Peak power output, the primary endpoint, was not significantly improved. This was a single-center proof-of-concept study; aerobic and walking improvements were mainly within-group findings or nonsignificant trends versus placebo.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.xcrm.2022.100633